Patent classifications
C07C211/30
NEW INDICATION OF CARDIOVASCULAR DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION
A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of a cardiovascular drug or a pharmaceutical acceptable salt thereof. The cardiovascular drug is selected from the group consisting of peripheral vasodilator reaming enhancer, angiotensin converting agent inhibitor, hypotension and shock therapeutic agent, diuretic, antiarrhythmic agent, antiarralciton drug, antihypertensive agent, anticoagulant thrombolytic agent, cardiac tonic, and intravenous (hemorrhoids) therapeutic agent. The cancer is selected from the group consisting of lung cancer, intestinal cancer, colorectal cancer, prostate cancer, liver cancer, bladder cancer, cervical cancer, breast cancer, and blood cancer.
NEW INDICATION OF CINACALCET HCL PHARMACEUTICAL COMPOSITION FOR TREATING CANCER
A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of Cinacalcet HCl or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, a gastrointestinal tract-related cancer, osteosarcoma, skin cancer, and blood cancer.
NEW INDICATION OF CINACALCET HCL PHARMACEUTICAL COMPOSITION FOR TREATING CANCER
A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of Cinacalcet HCl or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, a gastrointestinal tract-related cancer, osteosarcoma, skin cancer, and blood cancer.
NEW INDICATION OF ANTIBIOTIC DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION
A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of an antibiotic drug or a pharmaceutical acceptable salt thereof. The antibiotic drug is selected from the group consisting of an aminoglycoside antibiotic drug, an anti-fungal antibiotic drug, a Cephalosporin antibiotic drug, a -propionamide antibiotic drug, a chloramphenicol antibiotic drug, an erythromycin antibiotic drug, a penicillin antibiotic drug, and a tetracycline antibiotic drug. The cancer is selected from the group consisting of lung cancer, gastrointestinal tract cancer, colorectal cancer, prostate cancer, bladder cancer, cervical cancer, breast cancer, and blood cancer.
PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO
This document discloses molecules having the following formula (Formula One):
##STR00001##
and processes associated therewith.
PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO
This document discloses molecules having the following formula (Formula One):
##STR00001##
and processes associated therewith.
Pesticidal compositions and processes related thereto
This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.
Pesticidal compositions and processes related thereto
This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.
Process preparing of (E)-3-(4-methoxyphenyl)-N-methyl-N-((6,7,8,9-tetrahydro-5H-benzo-[7]annulen-2-yl)methyl)prop-2-en-1-amine
Provided is a new method for preparing (E)-3-(4-methoxyphenyl)-N-methyl-N-((6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)methyl)prop-2-en-1-amine as a drug intermediate.
Process preparing of (E)-3-(4-methoxyphenyl)-N-methyl-N-((6,7,8,9-tetrahydro-5H-benzo-[7]annulen-2-yl)methyl)prop-2-en-1-amine
Provided is a new method for preparing (E)-3-(4-methoxyphenyl)-N-methyl-N-((6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)methyl)prop-2-en-1-amine as a drug intermediate.